Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial
Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related...
Saved in:
Published in | Current controlled trials in cardiovascular medicine Vol. 18; no. 1; p. 536 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
13.11.2017
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients.
In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70-80 centers in nine countries across Europe.
There are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS.
European Union Clinical Trials Register, no: 2014-005260-15 . Registered on 15 July 2017. |
---|---|
AbstractList | BACKGROUNDAcute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients.METHODS/DESIGNIn this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70-80 centers in nine countries across Europe.DISCUSSIONThere are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS.TRIAL REGISTRATIONEuropean Union Clinical Trials Register, no: 2014-005260-15 . Registered on 15 July 2017. Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients. In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70-80 centers in nine countries across Europe. There are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS. European Union Clinical Trials Register, no: 2014-005260-15 . Registered on 15 July 2017. Abstract Background Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5′-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients. Methods/design In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70–80 centers in nine countries across Europe. Discussion There are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS. Trial registration European Union Clinical Trials Register, no: 2014-005260-15 . Registered on 15 July 2017. BackgroundAcute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5′-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients.Methods/designIn this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70–80 centers in nine countries across Europe.DiscussionThere are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS.Trial registrationEuropean Union Clinical Trials Register, no: 2014-005260-15. Registered on 15 July 2017. |
ArticleNumber | 536 |
Audience | Academic |
Author | Quintel, Michael Ranieri, V Marco Mancebo, Jordi Patroniti, Nicolò Jalkanen, Markku Vincent, Jean-Louis Maksimow, Mikael Bellingan, Geoff Pettilä, Ville Brealey, David Piippo, Ilse Mercat, Alain |
Author_xml | – sequence: 1 givenname: Geoff surname: Bellingan fullname: Bellingan, Geoff organization: Division of Critical Care, University College London Hospitals, NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK – sequence: 2 givenname: David surname: Brealey fullname: Brealey, David organization: The NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals, NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK – sequence: 3 givenname: Jordi surname: Mancebo fullname: Mancebo, Jordi organization: Department of Intensive Care, Hospital de la Santa Creu I Sant Pau, Carrer de Sant Quintí, 89, 08026, Barcelona, Spain – sequence: 4 givenname: Alain surname: Mercat fullname: Mercat, Alain organization: Service de Réanimation, CHU D'Angers, 4 Rue Larrey, 49100, Angers, France – sequence: 5 givenname: Nicolò surname: Patroniti fullname: Patroniti, Nicolò organization: Dipartimento di Emergenza e Urgenza, Azienda Ospedaliera San Gerardo, Via Giambattista Pergolesi 33, 20052, Monza, Italy – sequence: 6 givenname: Ville surname: Pettilä fullname: Pettilä, Ville organization: Department of Intensive Care, Helsinki University Hospital, Haartmaninkatu 4, Helsinki, 00290, Finland – sequence: 7 givenname: Michael surname: Quintel fullname: Quintel, Michael organization: Anesthesiology and Operative Intensive Care Medicine, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany – sequence: 8 givenname: Jean-Louis surname: Vincent fullname: Vincent, Jean-Louis email: jlvincent@intensive.org organization: Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. jlvincent@intensive.org – sequence: 9 givenname: Mikael surname: Maksimow fullname: Maksimow, Mikael organization: Faron Pharmaceuticals Oy, Joukahaisenkatu 6, 20520, Turku, Finland – sequence: 10 givenname: Markku surname: Jalkanen fullname: Jalkanen, Markku organization: Faron Pharmaceuticals Oy, Joukahaisenkatu 6, 20520, Turku, Finland – sequence: 11 givenname: Ilse surname: Piippo fullname: Piippo, Ilse organization: Faron Pharmaceuticals Oy, Joukahaisenkatu 6, 20520, Turku, Finland – sequence: 12 givenname: V Marco surname: Ranieri fullname: Ranieri, V Marco organization: Department of Anesthesia and Critical Care Medicine, Sapienza University of Rome, Policlinico Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29132404$$D View this record in MEDLINE/PubMed |
BookMark | eNptU8luFDEQbVAQWcgHcEGWuIRDB2-9cUCKIgKRkOAAZ8tjlzOOuu3Bdgc1X09NJoQE0T502fXeq011WO2FGKCqXjJ6yljfvs1M0FbUlHU150LW3dPqgHWyqVvOmr0H9n51mPM1pVIMQj6v9vnABJdUHjw5Po_TRiefYyDRkbIGAs55o81CdLAkawdl2bouvtaMU1aPSyQnPpSkbyDEOY8ItJMPPhdIYEkCE6eVDzoUsp4nHQiCITlIGGIFRddMv7nV3ozawCqi_zZuSaDLBEjDaBtdPJqZ_PRlTaZoIekCJCaS4QbjEG1mvCfIG4-emBZiMQO8Z5KXYFOc4B3JZbYL2aRYookjcUjXJGHsOPlfmKuJWEccRzRL8np8UT1zesxwfPc_qr5ffPh2_qn-_OXj5fnZ59o0LS21dtz2A4WmNaZhYISjzgHTTSNkJ0G6xsmu64TQ2Me-afvBsZ42fb9Fa9GLo-pyp2ujvlab5CedFhW1V7cPMV0pnYo3I6h26C1n0vXWttJK2lPOet4Z0RgQvXWo9X6ntZlXE1gD29GMj0Qfe4Jfq6t4ozAvwblEgZM7gRR_zJCLmnw2MI46AM5XsaGVvMUyGEJf_wO9jnMK2CrFu6HhrWwZ_4u60liADy5iXLMVVWeNbGk74Ieo0_-g8FiYPA4GnMf3RwS2I5gUc07g7mtkVG33Qe32QeE-qO0-qA45rx42557xZwHEb46SDKY |
CitedBy_id | crossref_primary_10_1186_s12931_019_0981_6 crossref_primary_10_1001_jama_2019_22525 crossref_primary_10_1080_13543784_2024_2315128 crossref_primary_10_3389_fphys_2021_774025 crossref_primary_10_1002_14651858_CD004477_pub3 crossref_primary_10_1016_j_chest_2018_10_022 crossref_primary_10_3389_fimmu_2019_01633 crossref_primary_10_1097_CCM_0000000000004104 crossref_primary_10_1164_rccm_201903_0550UP crossref_primary_10_1165_rcmb_2018_0054ED crossref_primary_10_1038_s41581_018_0005_7 crossref_primary_10_1126_scisignal_aba2940 crossref_primary_10_1080_17512433_2019_1643235 |
Cites_doi | 10.1084/jem.20040915 10.1164/ajrccm.149.3.7509706 10.1007/s00134-006-0080-2 10.4049/jimmunol.178.12.8127 10.1001/jama.2013.281053 10.1016/j.vph.2009.12.008 10.1056/NEJMoa062200 10.1016/S2213-2600(13)70259-5 10.1007/BF01709751 10.1056/NEJMoa1011802 10.1002/eji.200737793 10.1164/rccm.200406-763OC 10.1164/rccm.200805-722OC 10.1001/jama.2016.0291 10.1378/chest.07-2134 10.1097/00003246-198510000-00009 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7 10.1164/rccm.200505-693OC 10.1056/NEJM200005043421801 10.1128/JVI.01068-14 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. The Author(s). 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: The Author(s). 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2017 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13063-017-2234-7 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1745-6215 |
EndPage | 536 |
ExternalDocumentID | oai_doaj_org_article_698d214f8dd64d408021827c35ce38df A546069999 10_1186_s13063_017_2234_7 29132404 |
Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: European Union Seventh Framework Programme (FP7/2007-2013) grantid: 305853 – fundername: ; – fundername: ; grantid: 305853 |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AEGXH AENEX AFGXO AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ NPM O5R O5S PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX CITATION PGMZT ABVAZ AFNRJ 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO FRP K9. PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
ID | FETCH-LOGICAL-c560t-af2d890e56cc51ec3f0ffe1a553474e4f5f477733acac85689f180588c51ea383 |
IEDL.DBID | RPM |
ISSN | 1745-6215 |
IngestDate | Thu Sep 05 15:43:55 EDT 2024 Tue Sep 17 21:28:20 EDT 2024 Fri Aug 16 21:06:29 EDT 2024 Fri Sep 13 00:52:56 EDT 2024 Thu Feb 22 23:56:15 EST 2024 Fri Feb 02 03:59:09 EST 2024 Thu Sep 12 16:45:59 EDT 2024 Sun Jul 28 06:57:24 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | CD73 Interferon Vascular leakage ARDS |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c560t-af2d890e56cc51ec3f0ffe1a553474e4f5f477733acac85689f180588c51ea383 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683224/ |
PMID | 29132404 |
PQID | 2795264612 |
PQPubID | 44365 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_698d214f8dd64d408021827c35ce38df pubmedcentral_primary_oai_pubmedcentral_nih_gov_5683224 proquest_miscellaneous_1964268561 proquest_journals_2795264612 gale_infotracmisc_A546069999 gale_infotracacademiconefile_A546069999 crossref_primary_10_1186_s13063_017_2234_7 pubmed_primary_29132404 |
PublicationCentury | 2000 |
PublicationDate | 2017-11-13 |
PublicationDateYYYYMMDD | 2017-11-13 |
PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-13 day: 13 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Current controlled trials in cardiovascular medicine |
PublicationTitleAlternate | Trials |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 26903337 - JAMA. 2016 Feb 23;315(8):788-800 16714767 - N Engl J Med. 2006 Jun 15;354(24):2564-75 24141714 - JAMA. 2013 Nov 27;310(20):2191-4 20045081 - Vascul Pharmacol. 2010 May-Jun;52(5-6):199-206 16501946 - Intensive Care Med. 2006 Apr;32(4):545-52 18263687 - Chest. 2008 May;133(5):1120-7 24965449 - J Virol. 2014 Sep 1;88(17):10214-27 15583013 - J Exp Med. 2004 Dec 6;200(11):1395-405 22797452 - JAMA. 2012 Jun 20;307(23):2526-33 21470008 - N Engl J Med. 2011 Apr 7;364(14):1293-304 27403914 - Ann Am Thorac Soc. 2016 Oct;13(10 ):1742-1751 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10 16763220 - Am J Respir Crit Care Med. 2006 Sep 1;174(5):538-44 19011152 - Am J Respir Crit Care Med. 2009 Feb 1;179(3):220-7 15542793 - Am J Respir Crit Care Med. 2005 Feb 15;171(4):340-7 7509706 - Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24 10793162 - N Engl J Med. 2000 May 4;342(18):1301-8 17548651 - J Immunol. 2007 Jun 15;178(12):8127-37 18034430 - Eur J Immunol. 2007 Dec;37(12):3334-8 3928249 - Crit Care Med. 1985 Oct;13(10):818-29 24503265 - Lancet Respir Med. 2014 Feb;2(2):98-107 10399200 - Stat Med. 1999 Jun 15;18(11):1341-54 G Bellingan (2234_CR13) 2014; 2 RO Hopkins (2234_CR8) 2005; 171 C Rossi (2234_CR6) 2006; 32 NS Umapathy (2234_CR10) 2010; 52 M Zambon (2234_CR2) 2008; 133 SE Cochi (2234_CR3) 2016; 13 GR Bernard (2234_CR16) 1994; 149 World Medical Association (2234_CR17) 2013; 310 HP Wiedemann (2234_CR21) 2006; 354 MS Herridge (2234_CR7) 2011; 364 DM Finkelstein (2234_CR22) 1999; 18 AM Cheung (2234_CR9) 2006; 174 F Aeffner (2234_CR15) 2014; 88 J Kiss (2234_CR12) 2007; 37 JL Vincent (2234_CR19) 1996; 22 T Eckle (2234_CR14) 2007; 178 WA Knaus (2234_CR18) 1985; 13 The Acute Respiratory Distress Syndrome Network (2234_CR20) 2000; 342 VM Ranieri (2234_CR1) 2012; 307 LF Thompson (2234_CR11) 2004; 200 J Phua (2234_CR4) 2009; 179 G Bellani (2234_CR5) 2016; 315 |
References_xml | – volume: 200 start-page: 1395 year: 2004 ident: 2234_CR11 publication-title: J Exp Med doi: 10.1084/jem.20040915 contributor: fullname: LF Thompson – volume: 149 start-page: 818 year: 1994 ident: 2234_CR16 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.149.3.7509706 contributor: fullname: GR Bernard – volume: 32 start-page: 545 year: 2006 ident: 2234_CR6 publication-title: Intensive Care Med doi: 10.1007/s00134-006-0080-2 contributor: fullname: C Rossi – volume: 178 start-page: 8127 year: 2007 ident: 2234_CR14 publication-title: J Immunol doi: 10.4049/jimmunol.178.12.8127 contributor: fullname: T Eckle – volume: 310 start-page: 2191 year: 2013 ident: 2234_CR17 publication-title: JAMA doi: 10.1001/jama.2013.281053 contributor: fullname: World Medical Association – volume: 52 start-page: 199 year: 2010 ident: 2234_CR10 publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2009.12.008 contributor: fullname: NS Umapathy – volume: 354 start-page: 2564 year: 2006 ident: 2234_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa062200 contributor: fullname: HP Wiedemann – volume: 2 start-page: 98 year: 2014 ident: 2234_CR13 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(13)70259-5 contributor: fullname: G Bellingan – volume: 22 start-page: 707 year: 1996 ident: 2234_CR19 publication-title: Intensive Care Med doi: 10.1007/BF01709751 contributor: fullname: JL Vincent – volume: 364 start-page: 1293 year: 2011 ident: 2234_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1011802 contributor: fullname: MS Herridge – volume: 37 start-page: 3334 year: 2007 ident: 2234_CR12 publication-title: Eur J Immunol doi: 10.1002/eji.200737793 contributor: fullname: J Kiss – volume: 13 start-page: 1742 year: 2016 ident: 2234_CR3 publication-title: Ann Am Thorac Soc contributor: fullname: SE Cochi – volume: 171 start-page: 340 year: 2005 ident: 2234_CR8 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200406-763OC contributor: fullname: RO Hopkins – volume: 179 start-page: 220 year: 2009 ident: 2234_CR4 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200805-722OC contributor: fullname: J Phua – volume: 315 start-page: 788 year: 2016 ident: 2234_CR5 publication-title: JAMA doi: 10.1001/jama.2016.0291 contributor: fullname: G Bellani – volume: 133 start-page: 1120 year: 2008 ident: 2234_CR2 publication-title: Chest doi: 10.1378/chest.07-2134 contributor: fullname: M Zambon – volume: 13 start-page: 818 year: 1985 ident: 2234_CR18 publication-title: Crit Care Med doi: 10.1097/00003246-198510000-00009 contributor: fullname: WA Knaus – volume: 18 start-page: 1341 year: 1999 ident: 2234_CR22 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7 contributor: fullname: DM Finkelstein – volume: 307 start-page: 2526 year: 2012 ident: 2234_CR1 publication-title: JAMA contributor: fullname: VM Ranieri – volume: 174 start-page: 538 year: 2006 ident: 2234_CR9 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200505-693OC contributor: fullname: AM Cheung – volume: 342 start-page: 1301 year: 2000 ident: 2234_CR20 publication-title: N Engl J Med doi: 10.1056/NEJM200005043421801 contributor: fullname: The Acute Respiratory Distress Syndrome Network – volume: 88 start-page: 10214 year: 2014 ident: 2234_CR15 publication-title: J Virol doi: 10.1128/JVI.01068-14 contributor: fullname: F Aeffner |
SSID | ssj0043934 ssj0017864 |
Score | 2.2751222 |
Snippet | Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological... BackgroundAcute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved... BACKGROUNDAcute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved... Abstract Background Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 536 |
SubjectTerms | Acute respiratory distress syndrome Adenosine Administration, Intravenous ARDS Biological response modifiers Cause of Death CD73 Chronic obstructive pulmonary disease Clinical Protocols Clinical trials Comparative analysis Disease Progression Disease-Free Survival Double-Blind Method Drug dosages Drug therapy Edema Europe Female Humans Interferon Interferon beta Interferon beta-1a - administration & dosage Interferon beta-1a - adverse effects Length of Stay Male Medical research Medicine, Experimental Mortality Nucleotidases Palliative care Patients Research Design Respiration, Artificial Respiratory distress syndrome Respiratory Distress Syndrome, Adult - diagnosis Respiratory Distress Syndrome, Adult - diet therapy Respiratory Distress Syndrome, Adult - drug therapy Respiratory Distress Syndrome, Adult - mortality Respiratory failure Risk factors Severity of Illness Index Study Protocol Time Factors Tomography Treatment Outcome Vascular leakage Ventilators Viral antigens |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFI6yDyKIeLfrKkcQvEDZSZtbfVsXh0VY8cGFfQtpmuDAbCudWWH213tO2hmn-OCLbzNNZnL7ci7NyXcYeyNC4UVJRLe-iLnQ3uVOqzrXNVrjtfORpxf651_V2YX4cikv91J9UUzYQA88TNyxqkxTcBFN0yjRCLoaiiax9qX0oTRNTNKXy60zNchg1LKlGM8wuVHHK5TUdF6JEhnVocj1RAslsv6_RfKeTprGS-4poPkDdn-0HOFk6PFDdju0j9id8_Fs_PGte6e7lILQRUDDDgLxQzi_Adc2sHIxrDdUNP-Wc9TI-XLTwbsFNfYrMbUuseLIpUsZPIGc5as6hcpAyuUHRC7Rx9BjE3VYu5y79-m_U2RX3WF5ancXvU6tjcytK6BXvkCZd4idAroeUCljO-D8NX7v_5z5Q7MYrrDAlk_hIyQaXCBWiQ6hC2hqgwPUs013tbjBvo4h90v8mBKRPGEX88_fT8_yMdlD7tHoWucuFo2pZkEq7yUPvoyzGAN3UpZCiyCijEJrXZYO581IZarIzUwaQ7Ud-tlP2UHbteE5A4VSK3geovPoPtZkkgnu0XdTGp9UKmMftotvfw6cHjb5QkbZASkWkWIJKVZn7BPBY1eR6LjTAwSpHUFq_wXSjL0lcFkSGrioOILh7gP2l-i37IkU6EiirV5l7GhSEze7nxZv4WlHYbOyha4k2rVoq2bs9a6YfkkBdG1AAFniXSsUzhvP2LMBzbshFRUnWkaRMT3B-WTM05J28SNRkeM6oEYQh_9jkl6wuwXtUIqxLI_Ywbq_Di_R4lvXr9Lm_g1n6VgG priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFNa6FsZgjN3nrRsaDHYBk8iWJXkvoy0NZdBSxgp9E7IsdYHU7hx3kP36naMobs1gb4mlRLL96Vx0jr5DyHvuMstzJLq1mU-5tCY1UlSprMAar4z1LGzoH5-IozP-7bw43yJHm7MwmFa5kYlBUNetxT3ySSbLApQ3KOSJqXAXwPaTr1e_UqwfhXHWWEzjLtnJGMeA7c7-4cnp9yGiIJXgMarJlJgsQXZjBBNkNChInsqRXgr0_f8K6VtaapxBeUslzR6Rh9GWpHvrl_-YbLnmCbl3HKPlT-88OBiKDNLWUzD1qEPGCGNX1DQ1XRrv-hU2zU5TBjo6Xaxa-nGOg_0O3K0L6BjZdbGmJ0X3-bIKyTM0VPejSDfRedfBEJXrTcrMp_DfIderaqE9jDvks-Nokct1SXETmGItHuSroG1HQU3DONTYa_je3WQB0Hq-PtRCNwwLX2ggxqXIM9ECmCkY39RQ0Lx1ezn_A3ONSfgL-BhKkzwjZ7PDHwdHaSz_kFoww_rU-KxW5dQVwtqCOZv7qfeOmaLIueSO-8JzKWWeG3huqhCq9ExNC6WwtwHP-znZbtrGvSRUgBxzljlvLDiUFRppnFnw5oSEK6VIyOfNy9dXa5YPHbwjJfQaKRqQohEpWiZkH-ExdESC7nCh7S50XO9alKoGIHpV14LXHE80gycnbV5Yl6vaJ-QDgkujGEEwm3gaAuaLhFx6r-DgWoL1XiZkd9QTlr8dN2_gqaP4WeqbxZKQd0Mz_hJT6hoHANLIxJYJeG4sIS_WaB5uKSsZEjXyhMgRzkf3PG5p5j8DOTm8B9AR_NX_p_Wa3M9w7WE-Zb5Ltvvu2r0B666v3saF-xfFGlU7 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEI_nCXIg4udZPWUEwQ_ouW3z0Qoi5-FyCCs-uHBvIU0TXdhrtbsnrn-9M2m3XvEefNs26U6T_JKZaSa_YewZd6nlGRHd2tTHXFkTGyXLWJVojZfG-iR80J99kidz_vFUnO6wbXqrvgNXl7p2lE9q3i4Pf_3YvMMJ_zZM-Fy-XuE6TLuRuN6isuOxusqupTzjBPgZHzYVUPVmvN_YvPSxkWoKDP7_rtMXFNU4iPKCVpreYjd7cxKOuvG_zXZcfYddn_Ub5nev3Dge8gxC4wGtPXBEGmHsBkxdwcp4t95Q0fRznKCajpebBl4sSNjPQN-6xIo9wS6l9QTyoM_KED8DIcEfEONE612LIkq3NnFiXob_DuFeZYPlQe4Q0k7SejrXFdB3YKB0PERZAU0LqKlRDhh7jtft30AAqBbduRbYkiy8gcCNC0Q10SCeAe1vMIDKt2rOFr_xXfs4_CX-DNlJ7rH59MOX45O4zwARW7TE1rHxaZUXEyektSJxNvMT711ihMi44o574blSKssM9lsuZF74JJ-IPKfaBp3v-2y3bmr3gIHEpczZxHlj0acsyU7jiUWHTiq8U8iIvdoOvv7eEX3o4CDlUndI0YgUTUjRKmLvCR5DReLoDjea9qvup7yWRV6lCfd5VUlecTrUjM6cspmwLssrH7HnBC5N2MZBxRZ0ByLwfYmTSx8Jjt4lGvBFxA5GNXEFsOPiLTz1dgLpVBUCjV00YCP2dCimJymqrnYIIE1kbKnEfksitt-heWhSWiTE1cgjpkY4H7V5XFIvvgV-chwHVBP84X_IfcT2UpqAFFeZHbDddXvuHqOVty6fhLn7Bzk2VSE priority: 102 providerName: Scholars Portal |
Title | Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29132404 https://www.proquest.com/docview/2795264612/abstract/ https://search.proquest.com/docview/1964268561 https://pubmed.ncbi.nlm.nih.gov/PMC5683224 https://doaj.org/article/698d214f8dd64d408021827c35ce38df |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFNbaDsZgjN26eeuCBoNdwE1s62LvLQ0NJZASthX6JmRZ2gKJXZx0kP36nSPbWc3e9pKLJVu-fOdmHX2HkPfMxoYlSHRrYhcyaXSopchDmYM3nmvjIv9Cf34pLq7Y7JpfHxDerYXxSfsmX56Wq_Vpufzpcytv1mbY5YkNF_MJF4hDNjwkhzJJuhC9Ub9gYBPWTl9GqRhuQEnjVCUoY7CELMSqe3EWIQ8d69kiT9n_r2K-Y5n6WZN3zND0CXnc-o903JznU3Jgy2fkwbydIX9-79FkX1iQVo6Ce0ctskRos6O6LOhGO7vdYdN0EUZgl8PVrqIflzjYL8_XuoKOLaMu1vGkGDKvc58wQ31FP4oUE7WzNQyR260OI_3JH9vnd-UVtPtx9znsOFrL37qh-OKXYv0d5KigVU3BNMM4VJtb-F__nfmnxbJZyEI7VoUv1JPhUuSWqADAFBxuqilY26JaL3_DubaJ9yv46cuRvCBX0_Pvk4uwLfkQGnC9tqF2cZFmI8uFMTyyJnEj52ykOU-YZJY57piU8NA13LcUcJC5KB3xNMXeGqLtY3JUVqV9RagA3WVNZJ02EETm6JixyEAEJyRsyURAPncPX900zB7KR0SpUA1oFIBGIWiUDMgZwmPfEUm5_Yaq_qFaaCqRpUUcMZcWhWAFw1XMEL1Jk3Bjk7RwAfmA4FKoOuChwhU0KyDgfJGES405g3ASPPYsICe9niDypt_cwVO1KmejYplx8G7BYw3Iu30z7olpdKUFAClkX4sF3LcoIC8bNO8vqROKgMgeznvX3G8B-fSE5K08vv7vPd-QhzFKKKZXJifkaFvf2rfg7G3zAYj4tRyQ--Px7NsMvs_OLxdfB_7VCXzOWTrw4v8H2FZe3g |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829,74102,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwEDcwJEBCiG8CA4yExIcUrU4c2-EFjYmqwDrxsEl9sxzHhkpdMtIOqfz13DlutwiJtzbn9uz4fB_2-XeEvOYuszxHoFub-ZRLa1IjRZXKCrzxyljPwob-9EhMTvjXWTGLG27LmFa50YlBUdetxT3yvUyWBRhvMMgfz36lWDUKT1djCY1r5Dow5JjSJ2fbgItJJXg8yWRK7C1BX-OpJehlMIo8lQNbFCD7_1XMlyzTMGvykhka3yV3ov9I9_sJv0euuuY-uTGNJ-QPrtw-2BYWpK2n4N5RhygRxq6paWq6NN6t1kgaf08Z2OV0sW7p2zky-x3wWhfQMCLqYh1PiiHzaRUSZmio6EcRYqLzrgMWlVuZlJl34b9DflfVAj3w3eawI7eI37qkuPFLsf4OYlTQtqNgmoEPNfYcvncXJ_-0nvcXWegGVeEDDWC4FLElWhBgCg43NRSsbd2ezv9AX2Pi_QI-hnIkD8nJ-PPxwSSNJR9SC67XKjU-q1U5coWwtmDO5n7kvWOmKHIuueO-8FxKmecG3psqhCo9U6NCKWxtINp-RHaatnFPCBWgu5xlzhsLQWSFjhlnFiI4IeFJKRLyfjP5-qxH9tAhIlJC95KiQVI0SoqWCfmE4rFtiKDc4UHb_dBxjWtRqjpj3Ku6FrzmeIsZojdp88K6XNU-IW9QuDSqDphUGEF_AwL6iyBcer_gEE6Cx14mZHfQEpa8HZI34qmjylnqiwWSkFdbMv4S0-gaBwKkEX0tE_DeWEIe99K8HVJWMgRn5AmRAzkfjHlIaeY_AyA5zAPYBf70_916SW5OjqeH-vDL0bdn5FaG6xDzKfNdsrPqzt1z8O5W1YuwhP8CoF1TCA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFDYwpAkJIe4EBhgJiYsUtU4c2-EFjUE1Lpv2wKS9WY5jQ6UuGWmHVH495zhutgiJtzZ2e-z4XO3j7xDykrvM8hyBbm3mUy6tSY0UVSor8MYrYz0LG_oHh2L_mH85KU5i_tMyplVudGJQ1HVrcY98ksmyAOMNBnniY1rE0cfZ-7NfKVaQwpPWWE7jGrkOVnKK1QzkyRB8MakEj6eaTInJEnQ3nmCCjgYDyVM5sksBvv9fJX3JSo0zKC-ZpNltciv6knS3X_w75Kpr7pLtg3hafu_Kzb2hyCBtPQVXjzpEjDB2TU1T06XxbrXGptlRysBGp4t1S1_PkdjvgN26gI4RXRdrelIMn0-rkDxDQ3U_inATnXcdkKjcyqTMvAn_HXK9qhbaA90hnx2pRSzXJcVNYIq1eBCvgrYdBTMNdKix5_C9u8gCoPW8v9RCNwgL72gAxqWIM9ECM1NwvqmhYHnr9nT-B8Yak_AX8DGUJrlPjmefvu_tp7H8Q2rBDVulxme1KqeuENYWzNncT713zBRFziV33BeeSynz3MB7U4VQpWdqWiiFvQ1E3g_IVtM27hGhAvSYs8x5YyGgrNBJ48xCNCckPClFQt5uFl-f9SgfOkRHSuieUzRwikZO0TIhH5A9ho4I0B0etN0PHeVdi1LVGeNe1bXgNccbzRDJSZsX1uWq9gl5hcylUY3AosIM-tsQMF4E5NK7BYfQErz3MiE7o54g_nbcvGFPHdXPUl8IS0JeDM34S0ypaxwwkEYktkzAe2MJedhz8zClrGQI1MgTIkd8PprzuKWZ_wzg5LAOYCP44_8P6znZBunV3z4ffn1CbmQohphame-QrVV37p6Co7eqngUJ_gtQxlc0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+efficacy+and+safety+of+FP-1201-lyo+%28intravenously+administered+recombinant+human+interferon+beta-1a%29+and+placebo+in+the+treatment+of+patients+with+moderate+or+severe+acute+respiratory+distress+syndrome%3A+study+protocol+for+a+randomized+controlled+trial&rft.jtitle=Trials&rft.au=Bellingan%2C+Geoff&rft.au=Brealey%2C+David&rft.au=Mancebo%2C+Jordi&rft.au=Mercat%2C+Alain&rft.date=2017-11-13&rft.eissn=1745-6215&rft.volume=18&rft.issue=1&rft.spage=536&rft.epage=536&rft_id=info:doi/10.1186%2Fs13063-017-2234-7&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |